Literature DB >> 3708935

Acutely impaired renal function during intravenous administration of cyclosporine A: a cremophore side-effect.

G Thiel, M Hermle, F P Brunner.   

Abstract

The parenteral application of a cyclosporine A (CyA)-containing solution in high doses, 0.7 mg/kg/min, was associated with an acute reduction in renal blood-flow and a depression in creatinine clearance to approximately one half of control values. Exactly the same effect can be produced by the intravenous administration of the vehicle, cremophore, a polyoxyethylated castor-oil derivative. Although these observations are not of great clinical importance, since the doses of CyA used in man are much lower and the drug is generally taken orally, they are of considerable importance when studying the effects of CyA under experimental conditions. For the purpose of examining the influence of CyA on renal function, cremophore-containing solutions should be avoided.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708935

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  14 in total

1.  Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats.

Authors:  S Koehn; F J Frey; R F Speck; T Zeugin; T Schaffner; A Zimmermann; B M Frey
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

Review 2.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

3.  Cyclosporin reduces renal blood flow through vasoconstriction of arcuate arteries in the hydronephrotic rat model.

Authors:  L B Zimmerhackl; M Fretschner; M Steinhausen
Journal:  Klin Wochenschr       Date:  1990-02-01

4.  Inhibition of intestinal diamine oxidase by detergents: a problem for drug formulations with water insoluble agents applied by the intravenous route?

Authors:  J Sattler; R Hesterberg; U Schmidt; M Crombach; W Lorenz
Journal:  Agents Actions       Date:  1987-04

Review 5.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

6.  Effects of a selective adenosine A1 receptor antagonist on the development of cyclosporin nephrotoxicity.

Authors:  V S Balakrishnan; C J von Ruhland; D F Griffiths; G A Coles; J D Williams
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 7.  Adverse reactions and interactions of cyclosporin.

Authors:  J P Scott; T W Higenbottam
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

8.  Significance of cyclosporin-A-associated renal surface irregularities.

Authors:  J Cornish; M Vanderwee; G Findon; T Miller
Journal:  Br J Exp Pathol       Date:  1988-12

Review 9.  Micro/nanofabricated platforms for oral drug delivery.

Authors:  Cade B Fox; Jean Kim; Long V Le; Cameron L Nemeth; Hariharasudhan D Chirra; Tejal A Desai
Journal:  J Control Release       Date:  2015-08-02       Impact factor: 9.776

Review 10.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.